HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
USA - NASDAQ:HBIO - US4169061052 - Common Stock
0.59 USD
+0.02 (+3.51%)
Overall HBIO gets a fundamental rating of 3 out of 10. We evaluated HBIO against 58 industry peers in the Life Sciences Tools & Services industry. HBIO has a bad profitability rating. Also its financial health evaluation is rather negative. HBIO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year HBIO was profitable.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
Each year in the past 5 years HBIO had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -71.67%, HBIO is not doing good in the industry: 89.66% of the companies in the same industry are doing better.
HBIO has a Return On Equity of -364.88%. This is amonst the worse of the industry: HBIO underperforms 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of HBIO (56.89%) is better than 74.14% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HBIO has been increased compared to 1 year ago.
HBIO has more shares outstanding than it did 5 years ago.
HBIO has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.65, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
HBIO's Altman-Z score of -2.65 is on the low side compared to the rest of the industry. HBIO is outperformed by 81.03% of its industry peers.
HBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Altman-Z | -2.65 |
ROIC/WACCN/A
WACC10.54%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
HBIO has a worse Current ratio (0.81) than 91.38% of its industry peers.
HBIO has a Quick Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
HBIO has a worse Quick ratio (0.41) than 96.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The earnings per share for HBIO have decreased strongly by -71.43% in the last year.
The earnings per share for HBIO have been decreasing by -19.73% on average. This is quite bad
HBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.24%.
HBIO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.12% yearly.
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
3.2 Future
HBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.77% yearly.
The Revenue is expected to decrease by -1.21% on average over the next years.
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 29.50, which means the current valuation is very expensive for HBIO.
HBIO's Price/Earnings ratio is a bit cheaper when compared to the industry. HBIO is cheaper than 72.41% of the companies in the same industry.
When comparing the Price/Earnings ratio of HBIO to the average of the S&P500 Index (26.51), we can say HBIO is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 4.63, the valuation of HBIO can be described as very cheap.
HBIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.53. HBIO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 4.63 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 82.76% of the companies listed in the same industry.
HBIO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HBIO is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.36 | ||
| EV/EBITDA | 17.86 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 45.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.77%
EPS Next 3YN/A
5. Dividend
5.1 Amount
HBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HBIO (11/4/2025, 3:04:29 PM)
0.59
+0.02 (+3.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.21%
Inst Owner Change3.42%
Ins Owners3.72%
Ins Owner Change11.11%
Market Cap26.27M
Revenue(TTM)88.75M
Net Income(TTM)-57406000
Analysts80
Price Target2.04 (245.76%)
Short Float %1.46%
Short Ratio0.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)1.96%
Max EPS beat(2)75.49%
EPS beat(4)3
Avg EPS beat(4)-19.61%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-36.43%
EPS beat(12)5
Avg EPS beat(12)-34.08%
EPS beat(16)5
Avg EPS beat(16)-29.83%
Revenue beat(2)1
Avg Revenue beat(2)4.73%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)2
Avg Revenue beat(12)-5.25%
Revenue beat(16)3
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 4.63 | ||
| P/S | 0.3 | ||
| P/FCF | 6.36 | ||
| P/OCF | 3.97 | ||
| P/B | 1.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.86 |
EPS(TTM)0.02
EY3.39%
EPS(NY)0.13
Fwd EY21.61%
FCF(TTM)0.09
FCFY15.72%
OCF(TTM)0.15
OCFY25.21%
SpS1.99
BVpS0.35
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% | ||
| FCFM | 4.65% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.42% | ||
| Cap/Sales | 2.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 223.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.65 |
F-Score4
WACC10.54%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4466.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.77%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
What is the valuation status of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a valuation rating of 6 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Fairly Valued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
What is the expected EPS growth for HARVARD BIOSCIENCE INC (HBIO) stock?
The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -57.5% in the next year.